Geron (GERN) Capital Expenditures Growth (1y) (2011 - 2024)
Powered by 
Analysis
Geron (GERN) Capital Expenditures Growth (1y) (2011 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 39.02% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 30.84% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -22.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 9.68% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 1,133.33% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 142.64% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 53.76% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -320.31% |
| Jun 30, 2024 | -99.92% |
| Mar 31, 2024 | 142.77% |
| Dec 31, 2023 | 100.27% |
| Sep 30, 2023 | -98.99% |
| Jun 30, 2023 | 239.36% |
| Mar 31, 2023 | -126.26% |
| Dec 31, 2022 | -662.83% |
| Sep 30, 2022 | 5,818.69% |
| Jun 30, 2022 | -149.79% |
| Mar 31, 2022 | 94.12% |
| Dec 31, 2021 | -45.98% |
| Sep 30, 2021 | -89.13% |
| Jun 30, 2021 | -410.71% |
| Mar 31, 2021 | 1,608.84% |
| Dec 31, 2020 | -119.27% |
| Sep 30, 2020 | 191.41% |
| Jun 30, 2020 | 87.78% |
| Mar 31, 2020 | -116.25% |
| Dec 31, 2019 | 3.14% |